MRK Merck
- Official Name: MERCK & CO., INC.
- Headquarters: 126 East Lincoln Avenue, P.O. Box 2000, RAHWAY, NJ, 07065 US
- CEO: Robert M. Davis
- Website: merck.com
- Key Investor: VANGUARD GROUP INC | 10%
- Dedicated Investor: KAHN BROTHERS GROUP INC | 8.94%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 6.122 | 2.558 - (3.564) | ||
| 2025-07-21 | 2 | Lost by 1.966 | (4.757) - (2.791) | ||
| 2025-07-28 | 3 | Lost by 11.372 | 6.038 - 17.410 | ||
| 2025-07-29 | 2R | Lost by 2.763 | (2.502) - 0.261 | ||
| 2025-08-04 | 4 | Lost by 2.386 | (4.408) - (2.022) | ||
| 2025-08-07 | 1R | Won by 1.796 | 1.470 - (0.326) | ||
| 2025-08-11 | 5 | Won by 9.753 | 4.058 - (5.695) | ||
| 2025-08-18 | 6 | Won by 2.746 | 5.686 - 2.940 | ||
| 2025-08-20 | 1R | Won by 0.713 | (0.006) - (0.719) | ||
| 2025-08-21 | 2R | Won by 1.773 | 1.535 - (0.238) | ||
| 2025-08-25 | 7 | Lost by 0.971 | 1.334 - 2.305 | ||
| 2025-09-01 | 8 | Lost by 2.893 | (1.385) - 1.508 | ||
| 2025-09-03 | 2R | Lost by 0.371 | (1.509) - (1.138) | ||
| 2025-09-04 | 3R | Lost by 1.962 | (0.180) - 1.782 | ||
| 2025-09-08 | 9 | Won by 0.521 | (0.025) - (0.546) | ||
| 2025-09-15 | 10 | Lost by 10.525 | (3.671) - 6.854 | ||
| 2025-09-22 | 11 | Won by 2.507 | (0.730) - (3.237) | ||
| 2025-09-29 | 12 | Lost by 5.315 | (2.209) - 3.106 | ||
| 2025-10-06 | 13 | Won by 12.402 | 11.393 - (1.009) | ||
| 2025-10-13 | 14 | Won by 4.192 | (3.638) - (7.830) | ||
| 2025-10-20 | 15 | Lost by 0.630 | 0.764 - 1.394 |
Latest News
Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?
Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab derux...
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job?
On September 24, Merck & Co., Inc. (NYSE:MRK) announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig,...
$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit
A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarte...
Johnson & Johnson’s Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigati...
Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030
Key Stats for Merck StockCurrent Price: $148. 74Target Price (Mid): ~$166Street Target: ~$154Potential Total Return: ~12%Annualized IRR: ~3% / yearWha...
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit
SOUTH SAN FRANCISCO, Calif., September 28, 2026--Mission Bio, the single-cell multiomics leader, today announced that Merck & Co. and Incyte will ...
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and D...
CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes Ontario's decision to include CAPVAXIVE® in its publicly funded a...
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J., September 28, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. ("...
Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance Innovation
Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforc...
Merck's CAPVAXIVE Added To Ontario's Publicly Funded Adult Immunization Program
Merck (NYSE:MRK), known as MSD outside the United States and Canada, welcomes Ontario's decision to include CAPVAXIVE® in its publicly funded...
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data
Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimburse...
Merck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3
Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive ...
United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy
United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock i...
Earn 10-15% Potential Income: Monthly Options Series (Oct. 2026)
Build a disciplined options income strategy targeting 12â15% annually. Read the full analysis here.
Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks
In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda me...
Merck Is Up 40% This Year, but Is the Keytruda Rebuild Already Priced In?
Key Stats for Merck Stock52-Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR):...
Merck (MRK) Stock May Be 37% Undervalued On Fresh FDA Approval
Merck’s stock has had a strong multi year run, and with the shares closing at US$148.78 most recently, the key question for you is whether that leve...
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
RAHWAY, N.J., September 25, 2026--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and ...
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.0% on an annualized basis producing an average annual return of 1...
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with s...
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually recei...
Friday's session: top gainers and losers in the dow jones index
Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's s...
Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA
The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MS...
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks
Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversificationâread ...
Merck remigromig DME trial results raise safety concerns
Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued tw...
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
RAHWAY, N.J. & NUTLEY, N.J., September 25, 2026--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Ren...
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducibl...
Bank of America has strong message for Merck stock investors
A private meeting with the drugmaker’s top doctor points to the next make-or-break moment for shareholders.
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.
Merck Jumps as Winrevair Moves Earlier in PAH
The label now includes evidence from newly diagnosed patients, widening confidence before revealing commercial uptake.
Stay informed with the top movers within the dow jones index on Thursday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's s...
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's wide...
These Dow Jones Stocks Buck Index's Dud Performance
Some consumer, technology and industrial components form a solid core of possibilities for investors.
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema...
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its exper...
Thursday's session: top gainers and losers in the dow jones index
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compoundin...
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Merck reveals study success, and possible safety worries, for eye drug hopeful
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the...
FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell...
Trebellar Raises $18M Series A to Bring AI to Corporate Real Estate Management
SAN FRANCISCO, September 24, 2026--Trebellar, a company building AI-native decision making for corporate real estate management, today announced $18 m...
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportu...
Merck (MRK), What Is Behind The Fresh Attention Now?
Merck (MRK) just secured an FDA label update for WINREVAIR in pulmonary arterial hypertension, adding detailed Phase 3 HYPERION trial data that clarif...
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six mont...
You Only Need $2,000 and 1 Fund to Start Building a Dividend Portfolio. Here’s the ETF to Use
Most beginners chase the highest yield they can find and end up owning a ticking time bomb. One fund built around a completely different logic has qui...
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
RAHWAY, N.J., September 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pi...
Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in ...